Hillevax

Hillevax Equity

Delisted

The The Equity of Hillevax (HLVX) as of Nov 20, 2026 is 154.49 M USD. In the previous year, The Equity was 265.53 M USD — a change of -41.82% (lower).

Equity

154.49 MUSD

YoY

-41.82%

Last updated:

In 2024, Hillevax's equity was 154.49 M USD, a -41.82% increase from the 265.53 M USD equity in the previous year.

The Hillevax Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
-671,000.00 USD
Jan 1, 2020
-2.77 M USD
Jan 1, 2021
-100.76 M USD
Jan 1, 2022
267.23 M USD
Jan 1, 2023
265.53 M USD
Jan 1, 2024
154.49 M USD
The Hillevax Equity history
YEAREquityYoY
154.49 MUSD-41.82%
265.53 MUSD-0.64%
267.23 MUSD-365.22%
-100.76 MUSD+3,533.50%
-2.77 MUSD+313.26%
-671,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hillevax Stock analysis

What does Hillevax do? HilleVax, Inc. develops and commercializes novel vaccines, focusing on HIL-214, a bivalent virus-like particle (VLP) vaccine candidate for norovirus-induced acute gastroenteritis. The vaccine combines VLPs for norovirus genotypes GI.1 and GII.4 with an aluminum hydroxide adjuvant to enhance immune response. HIL-214 targets moderate-to-severe cases of norovirus infection, which causes symptoms like diarrhea, vomiting, and dehydration. The company's primary revenue stream will come from the future commercialization of HIL-214 after regulatory approval, with potential sales to healthcare providers and public health programs. Hillevax is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Hillevax's Equity

Hillevax's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Hillevax's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Hillevax's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Hillevax's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Hillevax’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Hillevax stock

The Equity of Hillevax is 154.49 M USD in 2024.

The Equity of Hillevax changed from 265.53 M USD to 154.49 M USD, representing a -41.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Hillevax since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Hillevax historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Hillevax

All Key Metrics — Hillevax